Recombinant interleukin-2 corrects in vitro the immunological defect of endometriosis

G. Melioli, C. Semino, A. Semino, P. L. Venturini, N. Ragni

Research output: Contribution to journalArticlepeer-review


PROBLEM: It has been shown recently that women with endometriosis have several immunological defects. In particular, these patients have a defect in peripheral blood natural killer cell activity and have lost their capacity of recognizing and lysing autologous endometrial cells. METHOD: We evaluated the effect of recombinant interleukin-2 (rIL-2) on peripheral blood lymphocytes obtained from both healthy donors and endometriosis patients. The generation of a strong cytolytic activity against autologous endometrial cells was obtained from both normal donors and endometriosis patients. RESULTS: Interestingly, these cytolytic cells belong to the T-cell lineage and do not recognize both autologous keratinocytes and allogeneic endometrial cells, thus suggesting a mechanism of specific recognition of autologous cells. CONCLUSION: The capability of restoring cytolytic activity using rIL-2 suggests a new immunotherapeutic approach for the treatment of severe endometriosis.

Original languageEnglish
Pages (from-to)218-227
Number of pages10
JournalAmerican Journal of Reproductive Immunology
Issue number4
Publication statusPublished - 1993


  • endometriosis
  • in vitro culture
  • Peripheral blood T lymphocytes
  • recombinant interleukin- 2

ASJC Scopus subject areas

  • Immunology
  • Obstetrics and Gynaecology


Dive into the research topics of 'Recombinant interleukin-2 corrects in vitro the immunological defect of endometriosis'. Together they form a unique fingerprint.

Cite this